Analysts Expect Evolent Health Inc (EVH) Will Post Earnings of -$0.05 Per Share

Brokerages expect Evolent Health Inc (NYSE:EVH) to report ($0.05) earnings per share for the current quarter, according to Zacks Investment Research. Ten analysts have issued estimates for Evolent Health’s earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.08). Evolent Health posted earnings per share of ($0.04) in the same quarter last year, which indicates a negative year-over-year growth rate of 25%. The company is expected to issue its next earnings report on Thursday, November 1st.

On average, analysts expect that Evolent Health will report full year earnings of ($0.10) per share for the current fiscal year, with EPS estimates ranging from ($0.17) to $0.01. For the next fiscal year, analysts forecast that the business will post earnings of $0.11 per share, with EPS estimates ranging from ($0.10) to $0.33. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Evolent Health.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Tuesday, August 7th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. Evolent Health had a negative return on equity of 1.82% and a negative net margin of 9.84%. The firm had revenue of $144.51 million during the quarter, compared to analyst estimates of $141.90 million.

A number of equities analysts have issued reports on EVH shares. ValuEngine upgraded Evolent Health from a “buy” rating to a “strong-buy” rating in a report on Friday, September 14th. Citigroup boosted their price target on Evolent Health from $25.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, October 4th. Canaccord Genuity boosted their price target on Evolent Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 13th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. Finally, KeyCorp boosted their price target on Evolent Health from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, August 20th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $29.69.

Evolent Health stock opened at $24.96 on Tuesday. The stock has a market capitalization of $1.98 billion, a P/E ratio of -35.66 and a beta of 1.20. Evolent Health has a 12-month low of $10.30 and a 12-month high of $29.05. The company has a current ratio of 2.59, a quick ratio of 2.59 and a debt-to-equity ratio of 0.12.

In other news, CEO Frank J. Williams sold 9,653 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $19.97, for a total value of $192,770.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Weinberg sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $27.12, for a total value of $406,800.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 214,260 shares of company stock worth $5,433,522. 4.82% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC purchased a new stake in shares of Evolent Health in the 2nd quarter worth $2,367,000. Rhumbline Advisers boosted its holdings in shares of Evolent Health by 17.5% during the 2nd quarter. Rhumbline Advisers now owns 68,036 shares of the technology company’s stock valued at $1,432,000 after purchasing an additional 10,113 shares during the last quarter. Standard Life Aberdeen plc lifted its holdings in shares of Evolent Health by 32.5% in the 2nd quarter. Standard Life Aberdeen plc now owns 1,469,650 shares of the technology company’s stock valued at $30,973,000 after acquiring an additional 360,206 shares during the last quarter. Waddell & Reed Financial Inc. lifted its holdings in shares of Evolent Health by 0.7% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,173,174 shares of the technology company’s stock valued at $24,695,000 after acquiring an additional 7,687 shares during the last quarter. Finally, Carillon Tower Advisers Inc. lifted its holdings in shares of Evolent Health by 72.7% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 1,633,453 shares of the technology company’s stock valued at $34,384,000 after acquiring an additional 687,893 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Read More: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply